Table 1. Baseline characteristics.
| Parameter | TDF/FTC (n = 20) | ABC/3TC (n = 20) |
| Anthropometric data | ||
| Mean age (95% CI), years | 45.9 (41.8–49.9) | 49.6 (44.0–55.1) |
| Male sex, n (%) | 14 (70.0) | 11 (55.0) |
| Active smokers, n (%) | 9 (45.0) | 6 (30.0) |
| Mean weight (95% CI), kg | 74.9 (67.3–82.5) | 73.2 (67.6–78.9) |
| Mean BMI (95% CI), kg/m2 | 25.0 (23.0–27.0) | 25.2 (24.2–26.1) |
| HIV-related data including HAART | ||
| Zidovudine/lamivudine at baseline, n (%) | 20 (100) | 20 (100) |
| PI at baseline, n (%) | 6 (30.0) | 6 (30.0) |
| Efavirenz at baseline, n (%) | 9 (45.0) | 11 (55.0) |
| Nevirapine at baseline, n (%) | 5 (25.0) | 3 (15.0) |
| Mean CD4+ cell count (95% CI), cells/mm3, | 540 (444–636) | 567 (447–687) |
| Median duration of HAART exposure (IQR), years | 8.9 (4.2–10.8) | 7.2 (4.5–10.4) |
| Median time since HIV-diagnosis (IQR), years | 10.2 (7.4–14.9) | 10.6 (8.0–11.7) |
| Bone-related data | ||
| Mean lumbar spine BMD (95% CI), g/cm2 | 0.99 (0.93–1.04) | 1.00 (0.95–1.05) |
| Mean hip BMD (95% CI), g/cm2 | 0.92 (0.86–0.98) | 0.90 (0.84–0.97) |
| Median plasma osteocalcin (IQR), mikg/L | 17.9 (15.3–22.5) | 21.0 (17.5–27.2) |
| Median plasma P1NP (IQR), mikg/L | 33.6 (29.8–48.2) | 51.5 (33.8–62.6) |
| Median plasma CTx (IQR), ng/mL | 0.25 (0.18–0.32) | 0.34 (0.22–0.49) |
| Median plasma osteoprotegerin (IQR), pmol/L | 3.4 (2.6–3.8) | 3.1 (2.3–3.9) |
| Median plasma alkaline phosphatase (IQR), U/L | 74.5 (65.5–90.5) | 82.0 (68.5–99.5) |
| Renal function-related data | ||
| Mean systolic blood pressure (95% CI), mmHg | 135 (127–142) | 133 (122–143) |
| Mean diastolic blood pressure (95% CI), mmHg | 84 (80–89) | 85 (79–90) |
| Mean fasting plasma glucose (95% CI), mmol/L | 5.4 (5.2–5.5) | 5.4 (5.2–5.6) |
| Median eCrCl a.m. Cockcroft-Gault (IQR), mL/min | 130 (118–140) | 120 (92–154) |
| Median urine NGAL/creatinine ratio (IQR) | 0.42 (0.08–1.72) | 0.28 (0.00–0.71) |
| Median urine cystatin C/creatinine ratio (IQR) | 0.92 (0.55–1.54) | 1.05 (0.54–1.15) |
| Median urine albumine/creatinine ratio (IQR) | 0.39 (0.23–0.88) | 0.47 (0.32–1.20) |
BMI = body mass index; PI = protease inhibitor; HAART = highly active antiretroviral therapy; HIV = human immunodeficiency virus; BMD = bone mass density; P1NP = procollagen type 1 N-terminal propeptide; CTx = type I collagen cross-linked C-telopeptide; eCrCl = estimated creatinine clearance; NGAL = neutrophil gelatinase-associated lipocalin. Normally distributed data are presented as means with 95% confidence interval (95% CI) in parenthesis. Skewed data are presented as medians with interquartile range (IQR) in parenthesis.